Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Subscribe To Our Newsletter & Stay Updated
